Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.76 -0.27%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $14.00 (from $16.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Securitize Corp (SECZ) PT Raised to $12 at StoneX on 'Innovation Exemption'
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Bank of Nanjing (601009:CH) PT Raised to RMB13.50 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
